Novel strategies by which to repair ischemic myocardium after myocardial infarction include the use of three-dimensional polymer scaffolds. A comparative study was carried out to assess the therapeutic potential of fibrin, collagen I, and Matrigel as injectable biopolymers for repair after myocardial infarction. Using a rat model of left coronary artery occlusion followed by reperfusion, local injection of the biopolymers into the infarct zone yielded significantly higher levels of capillary formation, when compared with the saline control group, at 5 weeks posttreatment. However, the degree of angiogenesis was not significantly different among the biopolymers. In addition, the collagen biopolymer significantly enhanced infiltration of myofibroblasts into the infarct area when compared with the control group. The results of this study highlight the potential clinical benefit of these biopolymers as injectable scaffolds or cell delivery vehicles to the infarct zone after infarction.

In this work, methacrylated gelatin (GelMA) based hydrogels were fabricated with carboxybetaine methacrylate (CBMA) to manipulate the properties of the gelatin-based hydrogels, since CBMA is a much smaller compound compared to gelatin. With the incorporation of CBMA, these hydrogels demonstrated better mechanical properties, a slower degradation rate, and a controlled drug release rate compared with the GelMA alone group. GelMA/CBMA hydrogels also showed good cell viability. As in the in vivo test, vascular endothelial growth factor (VEGF)-loaded GelMA/CBMA hydrogels displayed certain degrees of angiogenesis. These results indicate that GelMA/CBMA hydrogels are biocompatible, and the properties of GelMA/CBMA hydrogels can be easily tuned with the ratio of CBMA. These characteristics make the GelMA/CBMA hydrogel a promising material for drug delivery and tissue engineering.